EGFR and glioblastoma: With the help of CAR-T cells, they were able to target the EGFR VIII-containing GBM stem cells and identify the stem cells with this mutation.65 Although they do not respond to cultured normal tissue cells.66 EGFR-engineered immune cells have a significant anti-inflammatory effect in vitro and in vivo, but controlled and regulated toxicity such as skin, gastrointestinal, respiratory, and hypertension has been documented.67